Company Overview

SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies. The company operates within the biotechnology and oncology drug development industries, with an emphasis on peptide-based immunotherapeutic agents designed to stimulate the patient’s immune system to target cancer cells. SELLAS does not currently generate commercial product revenue and is primarily funded through equity financing and strategic collaborations, consistent with its clinical-stage profile.

The company’s core development programs are galinpepimut-S (GPS) and nelipepimut-S (NPS), both of which are cancer immunotherapies targeting specific tumor-associated antigens. SELLAS positions itself within the competitive immuno-oncology landscape by focusing on well-characterized antigens and combination strategies with existing cancer treatments. The company was founded in 2012 and became publicly traded following a merger with a special purpose acquisition company, enabling it to advance its pipeline through multiple clinical trials.

Business Operations

SELLAS operates as a single-reportable segment focused on oncology immunotherapy research and development. Its business activities center on preclinical research, clinical trial execution, regulatory engagement, and manufacturing coordination through third-party contractors. The company does not maintain in-house commercial manufacturing facilities and relies on external partners for clinical trial materials and related services.

Operations are conducted primarily in the United States, with clinical trials and research collaborations extending internationally. SELLAS controls the intellectual property and development rights for its lead candidates GPS and NPS, and it manages clinical development through a combination of internal scientific leadership and outsourced clinical research organizations. The company does not report material revenue from partnerships, and its operations are primarily supported by capital raises disclosed in SEC filings.

Strategic Position & Investments

Strategically, SELLAS is focused on advancing GPS through late-stage clinical development, particularly in hematologic malignancies, while continuing to evaluate NPS in solid tumor indications. Growth initiatives center on achieving positive clinical outcomes, securing regulatory milestones, and exploring potential combination therapies with established oncology treatments such as checkpoint inhibitors. The company has stated that it evaluates strategic partnerships to support development and potential commercialization, though no transformative acquisitions have been completed to date.

SELLAS has made targeted investments in expanding its clinical trial footprint and strengthening its intellectual property portfolio related to peptide-based cancer vaccines. Its strategy emphasizes capital efficiency and clinical differentiation rather than broad platform expansion. Data regarding long-term commercialization partnerships or licensing arrangements remains inconclusive based on available public sources.

Geographic Footprint

SELLAS is headquartered in the United States, with its principal executive offices located in New York, New York. The company’s operational presence is concentrated in North America, where corporate management, regulatory strategy, and primary investor relations activities are based.

Internationally, SELLAS has clinical trial activities and research collaborations in Europe and other select regions, reflecting the global nature of oncology drug development and patient recruitment. While the company does not maintain significant physical infrastructure outside the United States, its international influence is primarily driven by multinational clinical studies and regulatory interactions.

Leadership & Governance

SELLAS is led by an executive team with experience in oncology, biotechnology, and public company governance. Leadership emphasizes disciplined clinical development, scientific rigor, and value creation through data-driven milestones. The company operates under a board-governed structure typical of U.S.-listed biotechnology firms.

Key executives include:

• Angelos M. Stergiou, MD, ScD h.c. – President and Chief Executive Officer
• John E. Prendergast – Chief Financial Officer
• Rudolf H. von Roemeling, MD, PhD – Chief Medical Officer
• James L. Caruso – Chief Legal Officer and Corporate Secretary

The leadership team’s strategic vision centers on advancing immunotherapy candidates through clinical validation while maintaining compliance with regulatory and governance standards applicable to publicly traded life sciences companies.